Cabozantinib for previously treated locally advanced, unresectable or metastatic neuroendocrine tumours

Cabozantinib is currently in clinical development for treating locally advanced, unresectable or metastatic neuroendocrine tumours. A neuroendocrine tumour (NET) is a rare cancerous tumour that can develop in many different organs of the body. It affects the cells that release hormones into the bloodstream. There are several different types of NETs and the type a person has depends on the type of cell the cancer started in. Most NETs develop slowly over some years and may not cause symptoms in the early stages. The symptoms of a neuroendocrine tumour depend on where in the body it is and what hormones it produces. For example, a tumour in the digestive system may cause diarrhoea, constipation or tummy pains. Currently, there are few treatment options for patients with NETs that have spread around the body or cannot be operated on, leaving an unmet need for additional treatment options.